Novartis Acquires Anthos Therapeutics in $3.1B Deal to Bolster Stroke Prevention Drug
Novartis Expands Cardiovascular Portfolio with Anthos Therapeutics Acquisition
Pharmaceutical giant Novartis is set to acquire U.S.-based biotech company Anthos Therapeutics from Blackstone’s drug development division in a deal worth up to $3.1 billion. The purchase strengthens Novartis’ cardiovascular drug pipeline, particularly with the addition of abelacimab, a promising stroke prevention therapy.
Deal Structure and Strategic Implications
The agreement includes a $925 million upfront payment, with an additional $2.15 billion contingent on regulatory and sales milestones. Interestingly, abelacimab was originally developed by Novartis before Anthos was spun off in 2019, making this acquisition a strategic reclaiming of intellectual property with high market potential.
Abelacimab: A Potential Game-Changer for Stroke Prevention
Abelacimab is an experimental anticoagulant aimed at preventing strokes in patients with atrial fibrillation (AFib)—a common condition characterized by irregular heart rhythms. The drug is being positioned as a next-generation therapy with the potential to offer safer, more effective blood clot prevention compared to existing treatments.
Novartis’ Continued Expansion in Biopharma
This acquisition reflects Novartis’ ongoing investment in high-value biotech innovations. The company has been actively expanding its cardiovascular and immunology drug portfolio, reinforcing its position as a leader in next-generation therapeutics.
What’s Next?
With clinical trials progressing, investors and healthcare professionals will be closely watching how Novartis advances abelacimab through the regulatory process. If approved, the drug could reshape stroke prevention treatments, offering enhanced safety and efficacy for millions of patients worldwide.
